Another good update this morning and finall a bit of shareprice...

Another good update this morning and finall a bit of shareprice movement that appears sustainable. would have thought the ords would find strength above .04 in coming days, weeks. the oppies certainly are well bought and will come into their own once the ords hits .07. which will happne sooner rather than later imv. look at the last spike here .066 on neutral news.

this week they've said they have their US patent cleared and also an extensive list of what's going on in the asian region marketing wise. this movbe now have distribution channels in india, us, europe, australia and asia. how many asthmatics in these parts of the world ... lol

all good.

KARMELSONIX SALES AND MARKETING UPDATE REPORT ? ASIA PACIFIC REGION
APRIL 2010
Wednesday, 21st April
The purpose of this report is to provide KarmelSonix shareholders, investors and other interested parties with a comprehensive update regarding sales and marketing activities in the Asia Pacific Region, including work undertaken, current activities and future plans.
AUSTRALIA
? In addition to pharmacy partner, Clear Sales Australia (CSA), KarmelSonix has a number of the major pharmaceutical wholesalers, notably API and Sigma, agreeing to include the WheezoMeterTM in their warehouse and product line. This is a key step in the distribution of the product to the consumer via the retail pharmacy channel. Sales and marketing activities have commenced, with the 18‐strong national sales team of CSA starting to make initial presentations. CSA will target the top pharmacy buying groups as well as the key major pharmacies that are familiar with promoting medical devices such as blood glucose meters and CPAP machines for sleep apnoea. A complete creative marketing campaign is ready that incorporates in‐pharmacy posters, selling sheets and promotional flyers for patients.
? Trials of the PulmoTrack? are to commence in tertiary institutions including major adult teaching hospitals in Brisbane, Sydney and Melbourne, a leading Children?s Hospital and a world‐renowned asthma research institute. These are validation trials are designed to further demonstrate the utility of the KarmelSonix technology and products. We also have agreements in place to utilize the WheezoMetersTM in a number of asthma outpatient clinics.
? Australian Locum Medical Service in Melbourne, having purchased WheezoMetersTM last month, will shortly commence clinical usage with locum doctors in the field. Importantly, this is the first primary care doctors group in the world to use the technology in the field. The WheezoMeters? will be carried by the doctors when a home call is requested. This will provide the doctor with an on‐the‐spot wheeze rate reading.
? Two significant appointments have recently been made to the KarmelSonix team in Australia. Paul McWilliam, Sales and Marketing Manager who brings extensive experience in the respiratory marketplace, most recently 7 years with Tyco Healthcare, and Michelle Fernandez, Clinical Applications Specialist with over 10 years in clinical education and trials, and strong experience in the pharmacy area, particularly with Roche Diagnostics in the blood glucose / diabetes area.
Page 1 of 2
Paul is now working to drive the revenue growth in Australia, rolling out the plans with CSA, and developing relationships with Key Opinion Leaders and hospitals. Paul will also evaluate additional partners who can work with KarmelSonix to increase sales and distribution. Michelle is supporting our growth strategy principally in the training and education area among physicians, pharmacists and GP?s. Michelle is also directly responsible for all clinical trials in the region.
? A submission is being prepared for the Therapeutic Goods Administration for the WHolter? following receipt of CE Mark Medical approval. This is a significant step forward, as the WHolter? is a potential revenue generator in the home wheeze and cough analysis market, and is expected to provide revenue not only from sales of the unit but also from the provision of analytical services and sales of disposables.
ASIA
? Following the recent appointment of Resindo Medika, as distributor in Indonesia, KarmelSonix Asian distribution partner network now includes the following key parties:
o Pneumo Care Health ? North,West and East India
o Sapco Laboratories ? South India
o Celki Company ? Hong Kong
o MediPoint ? South Korea
o The Progressive Group ? China and Taiwan
o Resindo Medika ? Indonesia
? The Asian partners have been selected because of their substantial experience, and connections in the respiratory and sleep areas, with most having worked in these areas and their regions for more than a decade.
? Detailed discussions have commenced recently with potential distributors in Japan. This populous and wealthy market has a rapidly growing incidence of COPD and respiratory conditions. The potential distributors are substantial medical companies that also have extensive respiratory experience. KarmelSonix has also held preliminary discussions with the regulatory and government authorities as the Company prepares for the marketing approval process in Japan.
Additional announcements will be made in the short term covering further revenue models that are being finalized in the Asia Pacific region.